Benign recurrent intrahepatic cholestasis (BRIC) is a rare, inherited liver condition. It causes repeated “attacks” when bile cannot flow out of liver cells the way it should. During an attack, bile ingredients build up in the blood. This leads to very strong itching, yellow skin and eyes (jaundice), dark urine, pale stools, and tiredness. Between attacks, people often feel normal and tests can return to near normal. The word “benign” here means the attacks do not always lead to scarring or liver failure, especially if episodes are spaced out; however, some people can still develop liver changes over time, so follow-up matters. rarediseases.info.nih.gov+1

In BRIC, the problem is inside the liver (intrahepatic). There is no stone or tumor blocking the main bile duct. Instead, tiny transport proteins in the canalicular membrane of liver cells fail to move bile salts out. Two genes are most often involved: ATP8B1 (BRIC type 1) and ABCB11 (BRIC type 2). ABCB11 makes the bile salt export pump (BSEP). When these transporters do not work well, bile salts back up and trigger symptoms. PubMed+3Orpha+3NCBI+3

Benign Recurrent Intrahepatic Cholestasis (BRIC) is a rare inherited liver condition that causes repeated “flares” of poor bile flow inside the liver. During a flare, people develop severe itching (pruritus), dark urine, pale stools, and jaundice for weeks to months, then symptoms settle for long symptom-free periods. BRIC usually does not scar the liver the way progressive diseases do, but some people can show fibrosis, so medical follow-up is important. MedlinePlus+1

Two gene problems are known. BRIC type 1 comes from changes in ATP8B1; BRIC type 2 comes from changes in ABCB11, which makes the bile salt export pump (BSEP). Both types look very similar in daily life. Genetic testing can confirm the type and helps rule out related disorders in the PFIC spectrum. PMC+1

In BRIC, bile acids do not flow out of liver cells normally. That bile acid back-up drives the itch and jaundice. Blood tests show a cholestatic pattern and imaging shows no blocked bile ducts. The goal of care is to shorten flares, control itch, protect nutrition (especially fat-soluble vitamins), and avoid liver injury. MDPI+1

BRIC usually starts in the teens or early adulthood. Attacks can last weeks to months and then stop. The time between attacks can be months or years. Severity varies. Some people have only a few episodes in life. Others have many. Triggers like infection, certain medicines, stress, fasting, or hormonal shifts may bring on an episode in someone who already has the genes. rarediseases.info.nih.gov+1

---

Other names

BRIC has several names used in clinics and research. You may see: “Benign recurrent intrahepatic cholestasis”, “BRIC”, “BRIC1” (ATP8B1-related), “BRIC2” (ABCB11-related), and older terms like “benign recurrent cholestasis”. All describe the same pattern—recurrent cholestasis without permanent obstruction. Orpha+2Orpha+2

---

Types

Type 1 (BRIC1). This type is caused by changes in the ATP8B1 gene. ATP8B1 helps keep the canalicular membrane stable by flipping certain phospholipids. When it is weak, the membrane becomes less able to move bile. BRIC1 often shows normal or low GGT (a cholestasis enzyme), intense itching, and long symptom-free periods. Some people with ATP8B1 changes can sit on a spectrum that also includes the more severe PFIC1; careful follow-up is important. NCBI+1

Type 2 (BRIC2). This type is caused by changes in ABCB11, the gene for BSEP, the main pump that pushes bile salts out of liver cells. When BSEP is reduced, bile salts back up and cause cholestasis. Like BRIC1, GGT can be low or normal; bile acids are high. BRIC2 also sits on a spectrum with PFIC2, the more severe form. Genetic testing helps tell these apart. PMC+1

---

Causes

Important note: BRIC itself is genetic. The “causes” below include both the root genetic causes and common triggers that can precipitate or worsen attacks in someone who already carries BRIC genes.

1. ATP8B1 gene variants (BRIC1). Pathogenic changes reduce ATP8B1 function and lead to canalicular membrane instability and cholestasis episodes. NCBI

2. ABCB11 gene variants (BRIC2). Pathogenic changes reduce BSEP, lowering bile salt export and causing attacks. PMC+1

3. Autosomal recessive inheritance. A child inherits one pathogenic variant from each parent; parents are usually healthy carriers. rarediseases.info.nih.gov

4. Intercurrent infections. Viral or bacterial illnesses can stress the liver and trigger an episode. PMC

5. Certain medicines. Drugs that affect bile transport can precipitate cholestasis in susceptible people (e.g., some antibiotics, hormones, or anabolic steroids). Always review new medications. Merck Manuals

6. Hormonal shifts. Puberty or pregnancy-related changes in bile handling can act as a trigger in those with BRIC genes. NCBI

7. Fasting or crash dieting. Sudden changes in bile flow and metabolism during fasting may precipitate symptoms. PMC

8. Alcohol binges. Alcohol stresses hepatocytes and may worsen cholestasis in a vulnerable canalicular system. Merck Manuals

9. High environmental temperatures and dehydration. Physiologic stress may tip bile flow balance and bring on itching and jaundice. PMC

10. Major surgery or anesthesia. Peri-operative stress and drugs can trigger a new episode. PMC

11. Severe physical stress (over-exertion). Metabolic stress can contribute to attacks in predisposed people. PMC

12. Co-existing liver stressors (e.g., fatty liver). A second hit on the liver may lower bile flow reserve. Merck Manuals

13. Estrogens or progestins. Hormonal contraceptives can rarely impair bile flow; in BRIC they may trigger attacks—discuss options with clinicians. NCBI

14. Viral hepatitis exposure. Although BRIC is genetic, a new hepatitis can worsen cholestasis and confuse the picture. Testing helps separate causes. Merck Manuals

15. Herbal supplements. Some supplements are cholestatic; careful review is essential. Merck Manuals

16. Cholestatic drug reactions. Idiosyncratic cholestasis to medications can add to BRIC symptoms during an attack. Merck Manuals

17. Gut microbiome shifts. Illness, antibiotics, or diet change bile acid pools and may influence attacks (emerging concept). PMC

18. Genetic modifiers. Other transport genes may alter severity or frequency of BRIC episodes. PMC

19. Sleep loss and stress. Stress hormones can worsen perceived itch and overall symptom burden. PMC

20. Unknown or spontaneous triggers. Many attacks have no clear trigger even after review; this is common in BRIC. PMC

---

Symptoms

1. Severe itching (pruritus). This is the most common and most distressing symptom. It often starts on palms and soles and can be worse at night. It results from bile acids and other itch mediators building up in the blood and skin. AASLD+1

2. Jaundice. Skin and eyes turn yellow when bilirubin rises because bile cannot leave liver cells normally during an attack. Merck Manuals

3. Dark urine. Extra conjugated bilirubin is filtered by the kidneys and darkens urine. Merck Manuals

4. Pale or clay-colored stools. Less bile pigment reaches the intestine, so stools lose brown color. Merck Manuals

5. Fatigue. Poor sleep from itch and the metabolic stress of cholestasis cause tiredness. PMC

6. Nausea and reduced appetite. Backed-up bile salts and cytokines can reduce appetite during flares. rarediseases.info.nih.gov

7. Abdominal discomfort or right-upper-quadrant ache. The liver capsule may stretch slightly during an attack. Merck Manuals

8. Irritability and low mood. Chronic itch disrupts sleep and mood; treating itch helps quality of life. PMC

9. Weight loss during long attacks. Poor appetite and fat malabsorption can lead to weight change. Merck Manuals

10. Scratching marks and skin injury. Continuous scratching can break skin and cause infections; nail trimming and topical care help. AASLD

11. Dry skin. Xerosis is common with cholestatic itching and frequent washing. Emollients help. PMC

12. Fat malabsorption symptoms. Greasy stools or bloating may occur if bile acids in the gut are very low during a flare. Merck Manuals

13. Vitamin deficiency signs (A, D, E, K) over time. Long or frequent attacks can reduce absorption of fat-soluble vitamins; monitoring is wise. Merck Manuals

14. Photosensitivity-like discomfort. Some people report skin sensitivity during intense itch phases; sunscreen and loose clothing help comfort. PMC

15. Completely symptom-free periods. Many patients feel normal between attacks; this is a key clue to BRIC. rarediseases.info.nih.gov

---

Diagnostic tests

A) Physical examination

1. General inspection. Clinician looks for jaundice, scratch marks, and signs of distress from itch. This supports the diagnosis during attacks. Merck Manuals

2. Skin and eyes exam. Checking sclera for yellowing and skin for excoriations helps assess severity. Merck Manuals

3. Abdominal exam. Gentle palpation for liver size and tenderness; BRIC usually has no big liver enlargement, but mild tenderness can be present. Merck Manuals

4. Nutritional status check. Weight, BMI, and muscle mass are reviewed because long attacks can reduce intake and vitamin absorption. Merck Manuals

5. Stool and urine color review. Asking about pale stools and dark urine is a quick bedside clue to cholestasis. Merck Manuals

B) Manual tests / bedside maneuvers

6. Pruritus severity scaling. Simple numeric rating (0–10) or itch questionnaires track response to therapy across days and weeks. PMC

7. Sleep diary. A short daily note about sleep loss from itch guides step-up therapy. PMC

8. Medication and trigger review. A structured “brown-bag” check of all drugs, herbs, and recent stressors can uncover what triggered this attack. Merck Manuals

C) Laboratory and pathological tests

9. Serum bilirubin (total/direct). Usually high during an attack; returns toward baseline later. Pattern is conjugated (direct) hyperbilirubinemia. Merck Manuals

10. Alkaline phosphatase (ALP) and GGT. ALP rises with cholestasis. GGT is often normal or low in BRIC types, which helps separate BRIC from other cholestatic diseases. PMC

11. Serum bile acids. Usually elevated during attacks and track with itch. rarediseases.info.nih.gov

12. ALT and AST. Mild to moderate rises can occur; very high spikes suggest alternative or additional liver injury. Merck Manuals

13. Viral hepatitis panel. Rules out co-existing hepatitis (A, B, C, etc.) which can mimic or aggravate cholestasis. Merck Manuals

14. Autoimmune markers (AMA, ANA, SMA, IgG). Help exclude autoimmune cholestatic diseases like PBC or autoimmune hepatitis overlap. AASLD

15. Fat-soluble vitamins (A, D, E, K). Repeated attacks may lower levels; testing guides supplementation. Merck Manuals

16. Liver biopsy (during an attack). Shows canalicular cholestasis with minimal inflammation; between attacks, it can be normal. Biopsy helps when diagnosis is unclear. PMC

D) Electrodiagnostic tests

These are not routine for diagnosing BRIC, but may be used for symptom complications (e.g., sleep-deprivation-related issues). I list them for completeness because some diagnostic templates ask for them.

17. Actigraphy or sleep study. Documents sleep loss due to nocturnal itch and guides supportive care. PMC

18. Nerve conduction studies (rare). Only if there is suspected neuropathy unrelated to BRIC itself; usually not needed. PMC

E) Imaging tests

19. Ultrasound with doppler. Rules out gallstones, duct dilation, or vascular problems; in BRIC, ducts are typically not enlarged. Merck Manuals

20. MRCP (magnetic resonance cholangiopancreatography). Non-invasive view of bile ducts; BRIC usually shows no obstruction, supporting an intrahepatic process. Genetic testing often follows. Merck Manuals

21. Genetic testing (key confirmatory step). Sequencing ATP8B1 and ABCB11 identifies BRIC1 or BRIC2. Finding biallelic pathogenic variants confirms the diagnosis and separates it from other cholestatic disorders. Genetic counseling is recommended for families. NCBI+1

Non-pharmacological treatments (Therapies & others)

1. Skin hydration with emollients
   Daily thick moisturizers reduce dry skin and reduce scratch–itch cycles. This does not fix cholestasis, but less skin dryness means fewer triggers and less skin damage. Purpose: symptom relief. Mechanism: restores skin barrier, lowers nerve stimulation that worsens itch. AASLD

2. Cool/tepid bathing (avoid hot showers)
   Hot water worsens vasodilation and itch. Lukewarm baths with gentle cleansers calm the skin. Purpose: cut itch spikes. Mechanism: less heat-induced nerve firing and histamine release. AASLD

3. Loose, breathable clothing; short nails
   Soft fabrics lessen friction; trimming nails prevents skin breaks and infection from scratching. Purpose: reduce excoriations and infections. Mechanism: mechanical protection of skin barrier. AASLD

4. Topical menthol/cooling gels (non-drug cosmetics)
   Menthol cooling can briefly distract itch pathways (“counter-stimulation”). Purpose: acute relief on focal areas. Mechanism: TRPM8 activation modulates itch signaling. AASLD

5. Structured sleep hygiene
   Itch is often worse at night. Routine sleep timing, low bedroom temperature, and cotton sheets improve rest and reduce daytime fatigue. Purpose: protect sleep. Mechanism: lowers thermal triggers and arousal that intensify itch perception. PMC

6. UVB phototherapy (dermatology-supervised)
   If medicines fail or are not tolerated, targeted narrowband UVB can reduce cholestatic itch in small studies. Purpose: second-/third-line itch relief. Mechanism: immunomodulation and reduction of skin nerve itch signaling. PubMed+1

7. Avoid alcohol and hepatotoxic drugs
   During flares, alcohol and unnecessary liver-toxic medicines add stress to bile transport and can prolong symptoms. Purpose: protect liver. Mechanism: reduces metabolic and toxic load on hepatocytes. MDPI

8. Adequate hydration and fiber for constipation
   Constipation can increase enterohepatic recirculation of bile acids. Purpose: comfort and possibly lower bile acid reabsorption. Mechanism: faster gut transit may reduce reuptake. PMC

9. Nutritional counseling with MCT inclusion
   Medium-chain triglycerides (MCT) are better absorbed when bile is low. Work with a dietitian to add MCT oils or formulas while keeping essential fatty acids from other sources. Purpose: maintain energy and weight during flares. Mechanism: MCTs absorb directly via portal vein, needing less bile. PMC+1

10. Fat-soluble vitamin (A, D, E, K) monitoring & planning
    Deficiency is common in cholestasis. Plan testing and supplementation strategies. Purpose: prevent vision, bone, nerve, and bleeding problems. Mechanism: make up for poor micelle formation and absorption. PMC+1

11. Water-miscible vitamin formulations (TPGS, aqueous ADEK)
    Where available, water-soluble or TPGS forms improve uptake. Purpose: more reliable vitamin absorption. Mechanism: bypasses bile-dependent micelles. Medscape+1

12. Small, frequent, balanced meals
    Spacing dietary fat and using small meals can reduce post-meal itch spikes reported by some patients. Purpose: steadier digestion. Mechanism: smaller bile secretion bursts, less recirculation. PMC

13. Itch tracking & trigger diary
    Logging time, foods, baths, and stress helps personalize strategies. Purpose: self-management. Mechanism: behavioral feedback loops reduce exposure to personal triggers. PMC

14. Dermatology wound care for scratch lesions
    Dressings and antiseptic care prevent secondary infection. Purpose: protect skin while flares settle. Mechanism: barrier and antimicrobial support. PMC

15. Psychological support (CBT/mindfulness)
    Severe chronic itch harms mood and quality of life. Purpose: coping and sleep. Mechanism: reduces central amplification of itch perception. PMC

16. Sun protection
    Photosensitive skin or post-phototherapy skin needs SPF and protective clothing. Purpose: prevent burns and hyperpigmentation on inflamed skin. Mechanism: blocks UV injury. PubMed

17. Avoid very low-fat diets
    Ultra-low fat worsens essential fatty acid deficiency and vitamin uptake; use guided fat reduction plus MCT strategy instead. Purpose: avoid malnutrition. Mechanism: preserves essential fats and supports vitamin absorption plans. NASPGHAN

18. Physical activity as tolerated
    Gentle activity stabilizes mood and appetite; avoid overheating, which can worsen itch. Purpose: maintain function. Mechanism: endorphin and autonomic balance. PMC

19. Patient education on drug timing with resins
    If a bile acid resin is used, plan other medicines away from the resin to avoid absorption problems. Purpose: safer combos. Mechanism: resins bind many drugs in the gut. FDA Access Data

20. Care-team plan for rapid flare access
    Have a predefined plan for lab checks, nutrition support, and rescue options (e.g., rifampin, nasobiliary drainage) if severe. Purpose: shorten flare duration. Mechanism: early pathway-targeted steps reduce bile acid burden. PMC+1

---

Drug treatments

⚠️ These medicines are used by clinicians based on patient-specific factors. Doses below reflect label information (when available) or widely used clinical ranges; do not self-medicate.

1. Ursodiol (ursodeoxycholic acid, UDCA)
   Class: hydrophilic bile acid. Typical dose: 13–15 mg/kg/day in divided doses (label dosing for PBC). When/Why: often tried in BRIC to improve bile flow and cholestatic labs; also standard in PBC. Mechanism: replaces toxic bile acids, improves bile composition and secretion. Side effects: diarrhea, rare liver tests changes. Timing: with meals. Evidence suggests UDCA can reduce itch in cholestasis compared with cholestyramine in some studies, though results vary by disease. FDA Access Data+1

2. Cholestyramine (bile acid sequestrant)
   Class: anion exchange resin. Typical dose: 4 g 1–4×/day; take other meds 1 hour before or 4–6 hours after. When/Why: first-line for cholestatic pruritus. Mechanism: binds bile acids in the gut to reduce recirculation. Side effects: constipation, bloating; binds many drugs and vitamins. Timing: before meals is common. FDA Access Data+1

3. Rifampin (rifampicin)
   Class: antibiotic; potent pregnane X receptor (PXR) agonist. Typical dose: 150–300 mg twice daily for itch (off-label). When/Why: second-line when resins fail; can be very effective. Mechanism: induces hepatic enzymes, increases pruritogen metabolism/transport. Side effects: hepatotoxicity, drug interactions, red-orange body fluids. Timing: on empty stomach per label. Warning: monitor liver tests. FDA Access Data+1

4. Naltrexone (oral opioid antagonist)
   Class: opioid receptor antagonist. Typical dose: 25 mg daily, then 50 mg daily (off-label for cholestatic pruritus). When/Why: third-line for opioid-mediated itch pathways. Mechanism: blocks μ-opioid–mediated itch potentiation. Side effects: nausea, headache, possible withdrawal in opioid-exposed patients; rare liver enzyme changes. Timing: once daily. FDA Access Data

5. Sertraline (SSRI)
   Class: antidepressant. Typical dose: 50–100 mg/day (off-label for itch). When/Why: can help refractory cholestatic itch and mood/sleep. Mechanism: central modulation of itch perception via serotonin pathways. Side effects: GI upset, sleep change, sexual dysfunction; dose adjust in hepatic impairment. Timing: daily. MDPI

6. Phenobarbital (enzyme inducer; highly selective use)
   Class: barbiturate anticonvulsant. Typical use: low doses occasionally used historically to induce bile acid metabolism; modern use limited due to sedation and dependence risks. Mechanism: enzyme induction may alter pruritogens. Side effects: sedation, cognitive effects, dependence. Note: not routine first-line today. PMC

7. Ondansetron (5-HT3 antagonist) – adjunct
   Class: antiemetic. Use: can help nausea during flares; itch benefit inconsistent. Mechanism: 5-HT3 blockade may modulate itch signaling in some settings. Side effects: headache, constipation; QT caution. PMC

8. Gabapentin – adjunct for neuropathic itch component
   Class: neuromodulator. Typical dose: 100–300 mg at night, titrate. Why: helps sleep and neuropathic sensations in refractory cases; data are stronger in uremic itch but sometimes used in cholestasis. Side effects: sedation, dizziness; adjust in renal disease. NCBI

9. IBAT inhibitors: Odevixibat
   Class: ileal bile acid transporter (IBAT) inhibitor. Label dose (PFIC): per weight-based label; indicated for pruritus in PFIC (not specifically for BRIC). Why: lowers enterohepatic bile acid recycling; may help pruritus in related genetic cholestasis. Mechanism: blocks bile acid reuptake in ileum, lowering serum bile acids. Side effects: diarrhea, fat-soluble vitamin issues (monitor). Note: off-label in BRIC—specialist decision. FDA Access Data+1

10. IBAT inhibitors: Maralixibat
    Class: IBAT inhibitor. Label (ALGS & some PFIC ages): see label for age-based dosing. Why: approved for cholestatic pruritus in Alagille syndrome and PFIC (certain ages). Mechanism/risks: as above (odevixibat). Note: use in BRIC would be off-label and specialist-guided. FDA Access Data+1

11. Antihistamines (e.g., hydroxyzine) – symptomatic at night
    Class: H1 blockers. Why: itch in cholestasis is not mainly histamine-driven, but sedation can aid sleep. Mechanism: central sedation and some antipruritic effect. Side effects: drowsiness, anticholinergic effects. PMC

12. Naloxone (IV) in monitored settings
    Class: opioid antagonist. Why: short-acting parenteral antagonist sometimes tried in hospital for severe refractory itch. Mechanism/risks: acute withdrawal in opioid-tolerant, transient effect. Note: hospital-supervised only. PMC

13. Rifampin alternatives (careful): rifabutin
    Occasionally considered if rifampin interactions are problematic, but evidence is thinner; specialist decision only. Risks: similar interaction/hepatotoxicity concerns. PMC

14. Bile acid–binding colesevelam
    Newer resin with better tolerability for some patients; still binds bile acids. Risks: can bind other drugs, may worsen constipation. PMC

15. Topical anesthetics for localized pruritus
    Short-term, focal relief; avoid overuse on broken skin. Mechanism: local nerve blockade. Limits: brief benefit only. PMC

16. Pramoxine lotions
    Over-the-counter option that can reduce localized itch, especially at bedtime. Mechanism: topical anesthetic. PMC

17. Centrally acting antidepressants (mirtazapine) – selected cases
    May help sleep and perceived itch; evidence low-quality in cholestasis. Risks: sedation, weight gain. PMC

18. Benzodiazepines – avoid as “itch treatment”
    May be used for anxiety/insomnia but do not treat cholestatic itch and carry dependence and fall risks. Guidance: avoid for itch itself. PMC

19. Antibiotic stewardship while on rifampin
    Confirm drug interactions (e.g., OCPs, anticoagulants, antiretrovirals). Reason: rifampin induces metabolism, reducing other drug levels. FDA Access Data

20. Careful vitamin A/D/E/K supplement selection
    Drug–nutrient interactions (resins binding vitamins) require timing vitamins away from resins and periodic lab checks. FDA Access Data+1

---

Dietary molecular supplements

⚠️ Supplements can interact with medicines (especially resins and IBAT inhibitors). Discuss with your clinician.

1. Vitamin A (retinol/retinyl esters; water-miscible forms when possible)
   Dose: individualized; monitor levels. Function: vision, immunity, epithelial health. Mechanism: replaces bile-malabsorbed vitamin A; use water-miscible forms in cholestasis when available. PMC+1

2. Vitamin D3 (cholecalciferol; or calcifediol under specialist)
   Dose: guided by 25-OH vitamin D. Function: bone and muscle health. Mechanism: compensates for fat-malabsorption; may need higher or water-miscible forms. PMC+1

3. Vitamin E (prefer TPGS form in cholestasis)
   Dose: specialist-guided (TPGS). Function: antioxidant; nerve and muscle protection. Mechanism: TPGS is water-soluble, improving absorption without bile. Medscape

4. Vitamin K (phylloquinone; water-miscible)
   Dose: based on INR/levels. Function: clotting factor activation. Mechanism: corrects bile-related deficiency to prevent bleeding. PMC

5. MCT oil
   Dose: titrate with dietitian (often 10–30 mL with meals), while ensuring essential fatty acids elsewhere. Function: energy source during poor bile flow. Mechanism: direct portal absorption with minimal bile need. ScienceDirect+1

6. Calcium with vitamin D
   Dose: as per bone health needs. Function: support bone mineralization in chronic cholestasis with vitamin D deficiency risk. Mechanism: addresses secondary bone loss risk. PMC

7. Water-miscible multivitamin (ADEK pediatric/adult formulations where available)
   Dose: label-guided; often adjunct to individual vitamins. Function: broad micronutrient support. Mechanism: bypass bile-dependent micelles. MDPI

8. Phosphatidylcholine (dietary)
   Dose: varies; discuss with clinician. Function/Mechanism: membrane component; in some cholestatic disorders low biliary phospholipids worsen bile toxicity; dietary PC is supportive only (evidence limited). PMC

9. Omega-3 fatty acids (EPA/DHA)
   Dose: common 1–2 g/day EPA+DHA. Function: anti-inflammatory nutrition support; helps triglycerides. Mechanism: membrane and cytokine effects; does not fix cholestasis but supports cardiometabolic health. MDPI

10. Water-soluble forms of vitamins (liposome/cyclodextrin technologies)
    Dose: product-specific. Function: improve bioavailability of fat-soluble vitamins in low-bile states. Mechanism: alternative carriers allow absorption independent of micelles. MDPI

---

Immunity-booster / Regenerative / Stem-cell drugs

There are no FDA-approved “immunity boosters” or stem-cell drugs for BRIC. Below are research-stage or context-specific notes to inform discussions with your specialist—not treatment advice.

1. Mesenchymal stem cells (MSCs) – investigational for cholestatic diseases
   Early clinical research in PBC and other chronic liver diseases is exploring MSC infusions to modulate inflammation and fibrosis; not approved for BRIC. Dose/route: trial-specific (often IV; ~1–2×10^6 cells/kg). Function/mechanism: paracrine immunomodulation and pro-regenerative signaling; evidence remains preliminary. PMC+1

2. Engineered hepatocyte-like cells – investigational
   Programs are studying engineered cells to replace liver function in advanced liver disease; not approved for cholestatic itch or BRIC. Function/mechanism: cell replacement; clinical trials just beginning. Mayo Clinic News Network

3. MSC therapy in PSC/PBC trials
   Some trials enroll PSC/PBC patients to test safety and biochemical changes; no standard of care. Function: experimental symptom and fibrosis modulation. ISRCTN Registry

4. Hematopoietic stem cell approaches – case-specific
   Transplant-related settings (e.g., antibody-mediated issues post-transplant) have case reports; not BRIC care. Mechanism: immune reset in rare contexts. ScienceDirect

5. MSC dosage strategies under study
   Liver disease trials explore dosing (e.g., ≈1 million cells/kg); investigational. Mechanism: anti-inflammatory, anti-fibrotic paracrine effects. BioMed Central

6. Regenerative nutrition & exercise
   While not “drugs,” evidence supports nutrition (adequate protein, vitamins A/D/E/K) and activity for liver health during chronic disease; these are standard supportive measures, not regenerative cures. PMC

---

Procedures / Surgeries

1. Endoscopic Nasobiliary Drainage (ENBD)
   A temporary thin tube is placed via the nose into the bile ducts during ERCP to drain bile externally. In BRIC case reports, ENBD can rapidly relieve severe pruritus and cholestasis when medications fail. Why: short-term bile diversion to break a disabling flare. PMC+1

2. Albumin dialysis (MARS®)
   Extracorporeal albumin dialysis removes albumin-bound toxins (bile acids, bilirubin) to relieve refractory cholestatic pruritus. Benefit is often temporary, used as a bridge in severe cases. Why: rescue therapy when itch is intractable and quality of life is poor. Journal of Hepatology+1

3. Therapeutic plasmapheresis
   Plasma exchange can reduce circulating pruritogens (e.g., autotaxin activity), with case reports of fast itch relief—including in BRIC2. Why: severe flares unresponsive to standard therapy. PMC+1

4. Partial External Biliary Diversion (PEBD)
   A surgical bypass routes a portion of bile to an external stoma, reducing enterohepatic bile acid recycling. It is established in PFIC and sometimes considered in selected, extremely refractory cholestatic syndromes; stoma-related complications are possible. Why: long-term itch control when all else fails. PubMed+1

5. Liver transplantation (rare in BRIC)
   BRIC is usually “benign” without progressive failure. Transplant is reserved for exceptional, life-altering, treatment-refractory pruritus or unexpected liver failure. Why: last resort after exhausting all other options. PMC

---

Preventions (practical)

1. Avoid alcohol during and between flares. Why: protects bile transport and hepatocytes. MDPI

2. Review all meds and supplements with a clinician to avoid hepatotoxic or cholestatic agents. PMC

3. Get vaccinated per liver-disease guidance (e.g., hepatitis A/B) after clinician review. Goal: reduce secondary hits to liver. PMC

4. Maintain healthy weight and activity to support metabolic liver health. PMC

5. Plan early care for flares (labs, itch steps, nutrition). MDPI

6. Monitor fat-soluble vitamins regularly and supplement as needed. PMC

7. Use MCT strategy (with dietitian) during poor appetite or steatorrhea. ScienceDirect

8. Protect skin: moisturize, tepid baths, menthol gels, short nails. AASLD

9. Limit very hot environments and tight clothing to reduce itch triggers. AASLD

10. Arrange genetics counseling/testing for family planning and accurate diagnosis. MedlinePlus

---

When to see a doctor

See a liver specialist at the start of a flare, not just when symptoms are severe—especially if itch prevents sleep, jaundice deepens, urine becomes very dark, stools turn pale, you are pregnant, you lose weight, or you develop bleeding/bruising (possible vitamin K deficiency). Seek urgent care for confusion, severe abdominal pain, fever, GI bleeding, or signs of infection. Genetic confirmation and a standing flare plan improve outcomes. MedlinePlus+1

---

Foods to emphasize — and to limit/avoid

Eat more of:

1. Balanced proteins (fish, poultry, legumes) to maintain muscle. PMC
2. Fruits/vegetables for fiber and micronutrients (choose ones you tolerate). PMC
3. MCT-containing options (oils or prescribed formulas) for energy. ScienceDirect
4. Whole grains for fiber to support bowel regularity. PMC
5. Water-miscible ADEK multivitamin (if prescribed) and calcium-vitamin D. MDPI

Limit/avoid:

1. Alcohol (any amount) during and between flares. MDPI
2. Very high-fat, greasy meals (can aggravate symptoms). NASPGHAN
3. Herbal products with unknown liver safety. PMC
4. Excess vitamin A without monitoring (risk of toxicity). MDPI
5. Ultra-low-fat diets (risk nutrient deficits)—use dietitian-guided fat + MCT balance. NASPGHAN

---

Frequently Asked Questions

1) Is BRIC “benign”—can it damage my liver?
Usually BRIC does not lead to cirrhosis, but some patients show fibrosis and very rarely need transplant for intolerable pruritus; regular follow-up is wise. MedlinePlus+1

2) What triggers flares?
Often unknown. Infections, certain drugs, hormones, or stress may precede attacks, but proof is limited; keeping a diary may help. MedlinePlus

3) Which test confirms BRIC?
Genetic testing for ATP8B1 (BRIC1) and ABCB11 (BRIC2) with clinical context; imaging excludes obstruction. Gastro Journal

4) What is the stepwise treatment for itch?
Start with lifestyle/skin care → cholestyramine → rifampin → opioid antagonists (naltrexone) → sertraline → dermatology phototherapy; rescue with ENBD, MARS, or plasmapheresis in selected cases. PMC+1

5) Do antihistamines work?
They mostly help sleep; cholestatic itch is not mainly histamine-driven. PMC

6) Are IBAT inhibitors for BRIC?
IBAT inhibitors (odevixibat/maralixibat) are approved for PFIC/ALGS pruritus, not BRIC. Use in BRIC is off-label and specialist-guided. FDA Access Data+1

7) Is UDCA useful in BRIC?
UDCA is widely used to improve bile flow and labs; itch benefit varies by condition. FDA Access Data+1

8) How does rifampin help itch?
By inducing liver enzymes and transporters that clear pruritogens; monitor liver tests and interactions. FDA Access Data

9) Can phototherapy help?
Yes—small series show UVB reduces cholestatic itch when drugs fail. PubMed

10) Will I need surgery?
Most patients won’t. Rarely, ENBD, PEBD, or albumin dialysis are used for refractory cases; transplant is exceptional. PMC+1

11) What about vitamins?
Check A, D, E, K regularly; use water-miscible forms if possible; time supplements away from cholestyramine. PMC+1

12) Can pregnancy worsen flares?
Hormonal shifts can affect cholestasis; close obstetric–hepatology coordination is essential. PMC

13) Does bilirubin level track itch?
Poorly—itch can be severe with modest bilirubin, because multiple mediators drive pruritus. Frontiers

14) Are stem-cell therapies available now?
Not for BRIC. MSC approaches remain investigational in other liver diseases. PMC

15) How do I prepare for a flare?
Have a written plan: prompt labs, medication ladder for itch, nutrition/vitamin adjustments, and quick access to specialist rescue options. MDPI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 21, 2025.